Skip to main content

Table 2 Progression-free survival (PFS) outcomes for previously-treated patients with advanced MCC after treatment with avelumab (anti-PD-L1) compared with PFS rates from previous chemotherapy trials (historical controls)

From: Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Anti-neoplastic agent(s) Median PFS, months (95% CI) PFS rate at 12 months, % (95% CI) Reference
Avelumab (N = 88) 2.7 (1.4–6.9) 30 (21–41) [39]
Cowey 2017 (n = 20) 2.1 (1.0–3.2) 0 [42]
Becker 2016 (n = 34) 3.0 (2.6–3.1) 0 [43]
Iyer 2016 (n = 30) 2.0 (NA [range: 0.4–11.6]) 0* [14]
  1. The most common second-line chemotherapy was topotecan. NA, not available; *based on PFS range (11–354 days) and Kaplan-Meier PFS estimates